retatrutide trial The numbers from Lilly's Phase 3 dropped this week and I haven't been able to stop thinking about them. Not only as a doctor but as a long-term GLP-1 user retatrutide clinical trial status Retatrutide,

Around six months after giving birth to her second daughter, Adira, and after she stopped breastfeeding, she began weekly injections

The GLP-1 landscape is evolving quickly

Each formulation has distinct pharmacokinetic properties that determine how long the medication remains active in the body after administration or discontinuation

It takes a few weeks for the body to adjust to the medication and show visible weight loss, after which most patients lose 1-3 pounds per week

Weight loss typically continues, with clinical trials showing that semaglutide 2.4 mg (Wegovy) produces average weight loss of approximately 15% by week 68, while tirzepatide (Zepbound) has demonstrated weight loss of approximately 15-21% across different doses by week 72

Key Takeaways Retatrutide is an emerging medication for weight management and metabolic health that is expected to become more widely available around 2026